Schulman Associates IRB, Inc. Acquires Independent IRB, Inc.
Schulman Associates Institutional Review Board, Inc. announced the acquisition of Florida-based Independent Investigational Review Board, Inc. The transaction allows both organizations, which protect the rights of human research subjects, to provide a more comprehensive suite of review services for pharmaceutical, medical device, Contract Research Organization (CRO) and clinical research site customers.
"The strengths of the two organizations are remarkably complimentary," said Michael Woods, President and CEO of Schulman. "We are very excited by the added resources and capabilities Independent brings to the combined company."
With offices in Cincinnati, Ohio, and Plantation, Fl., the combined organization will aim to provide the highest level of quality research review services for a very broad range of therapeutic areas and types of human subject research. Separately, each organization is accredited by Association for the Accreditation of Human Research Protection Programs (AAHRPP), and each has a clean recent audit history with Food and Drug Administration. Both organizations, in business more than 20 years, also enjoy strong reputations for performing thoughtful and rigorous reviews while providing the highest level of customer service available.
"Joining with Schulman allows Independent to provide the advantages of enhanced WebPortal and IT features to our established customer base," said Kim Lerner, outgoing CEO of Independent.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
